ZA201108587B - Disubstituted phthalazine hedgehog pathway antagonists - Google Patents
Disubstituted phthalazine hedgehog pathway antagonistsInfo
- Publication number
- ZA201108587B ZA201108587B ZA2011/08587A ZA201108587A ZA201108587B ZA 201108587 B ZA201108587 B ZA 201108587B ZA 2011/08587 A ZA2011/08587 A ZA 2011/08587A ZA 201108587 A ZA201108587 A ZA 201108587A ZA 201108587 B ZA201108587 B ZA 201108587B
- Authority
- ZA
- South Africa
- Prior art keywords
- hedgehog pathway
- pathway antagonists
- disubstituted phthalazine
- phthalazine hedgehog
- disubstituted
- Prior art date
Links
- 241000289669 Erinaceus europaeus Species 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21862809P | 2009-06-19 | 2009-06-19 | |
| PCT/US2010/038568 WO2010147917A1 (en) | 2009-06-19 | 2010-06-15 | Disubstituted phthalazine hedgehog pathway antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201108587B true ZA201108587B (en) | 2013-05-29 |
Family
ID=42332981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2011/08587A ZA201108587B (en) | 2009-06-19 | 2011-11-22 | Disubstituted phthalazine hedgehog pathway antagonists |
Country Status (35)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201071248A1 (ru) * | 2008-04-29 | 2011-06-30 | Эли Лилли Энд Компани | Дизамещенные фталазиновые антагонисты пути hedgehog |
| NZ591945A (en) * | 2008-11-03 | 2012-10-26 | Lilly Co Eli | Disubstituted phthalazine hedgehog pathway antagonists |
| BRPI0921782A2 (pt) | 2008-11-17 | 2019-09-24 | Lilly Co Eli | antagonistas da via hedgehog de piridazina tetrassubstituída |
| AU2009314288B2 (en) * | 2008-11-17 | 2013-05-02 | Eli Lilly And Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| CA2829755A1 (en) | 2011-03-23 | 2012-09-27 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| GB201311953D0 (en) * | 2013-07-03 | 2013-08-14 | Redx Pharma Ltd | Compounds |
| US9814703B2 (en) | 2013-11-14 | 2017-11-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of BMP signaling |
| CN105017140B (zh) * | 2014-04-28 | 2017-12-29 | 复旦大学 | 邻氨基苯甲酰胺化合物及其制备方法和用途 |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| CN105985319B (zh) * | 2015-02-11 | 2019-02-26 | 复旦大学 | 芳基酞嗪化合物及其制备方法和用途 |
| CN105985320B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 苄基酞嗪化合物及其制备方法和用途 |
| CN105985321B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 吡唑酞嗪化合物及其制备方法和用途 |
| US10369147B2 (en) | 2015-06-04 | 2019-08-06 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
| EP3303289A4 (en) | 2015-06-05 | 2018-11-14 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| CN106279114B (zh) * | 2016-08-04 | 2019-01-29 | 东南大学 | 一种Taladegib的合成方法 |
| US10548908B2 (en) | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
| CN106831718B (zh) * | 2016-12-30 | 2019-05-07 | 上海科技大学 | 平滑受体配体及其应用 |
| EP3624798A1 (en) | 2017-05-18 | 2020-03-25 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
| WO2021261601A1 (ja) | 2020-06-26 | 2021-12-30 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
| WO2022081661A1 (en) * | 2020-10-13 | 2022-04-21 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025188802A1 (en) | 2024-03-05 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
| WO2025189041A1 (en) * | 2024-03-07 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025242197A1 (zh) * | 2024-05-24 | 2025-11-27 | 成都思倍博医药科技有限公司 | 氘代的Hedgehog通路SMO受体抑制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (enExample) | 1977-06-03 | 1981-03-07 | Pfizer | |
| CA2237273C (en) | 1996-01-15 | 2009-01-13 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
| EP1067939B1 (en) | 1998-04-09 | 2015-09-16 | The Johns Hopkins University | Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways |
| GB0013674D0 (en) | 1999-06-08 | 2000-07-26 | Lorantis Ltd | Therapeutic use |
| WO2003011219A2 (en) * | 2001-07-27 | 2003-02-13 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| ATE404200T1 (de) | 2002-04-22 | 2008-08-15 | Univ Johns Hopkins Med | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
| WO2004020599A2 (en) | 2002-08-29 | 2004-03-11 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
| TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
| US8338591B2 (en) | 2004-05-08 | 2012-12-25 | Novartis International Pharmaceutical Ltd. | 3-aryl-5,6-disubstituted pyridazines |
| KR20170001725A (ko) | 2004-09-02 | 2017-01-04 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| EP1900731A1 (de) * | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| JP5550352B2 (ja) * | 2007-03-15 | 2014-07-16 | ノバルティス アーゲー | 有機化合物およびその使用 |
| AU2008269128B2 (en) * | 2007-06-25 | 2012-08-02 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| WO2009035568A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
| WO2009074300A2 (en) * | 2007-12-13 | 2009-06-18 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| EA201071248A1 (ru) * | 2008-04-29 | 2011-06-30 | Эли Лилли Энд Компани | Дизамещенные фталазиновые антагонисты пути hedgehog |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| EP2321298B1 (en) * | 2008-08-04 | 2013-10-02 | Amgen Inc. | Aurora kinase modulators and methods of use |
| NZ591945A (en) | 2008-11-03 | 2012-10-26 | Lilly Co Eli | Disubstituted phthalazine hedgehog pathway antagonists |
| BRPI0921782A2 (pt) | 2008-11-17 | 2019-09-24 | Lilly Co Eli | antagonistas da via hedgehog de piridazina tetrassubstituída |
| AU2009314288B2 (en) | 2008-11-17 | 2013-05-02 | Eli Lilly And Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2010
- 2010-06-08 AR ARP100102003A patent/AR077014A1/es active IP Right Grant
- 2010-06-10 JO JO2010188A patent/JO2931B1/en active
- 2010-06-11 TW TW099119158A patent/TWI385165B/zh not_active IP Right Cessation
- 2010-06-15 PT PT107267569T patent/PT2443104E/pt unknown
- 2010-06-15 MY MYPI2011006137A patent/MY156667A/en unknown
- 2010-06-15 EP EP10726756.9A patent/EP2443104B1/en active Active
- 2010-06-15 MX MX2011014029A patent/MX2011014029A/es active IP Right Grant
- 2010-06-15 HR HRP20130408AT patent/HRP20130408T1/hr unknown
- 2010-06-15 US US12/815,439 patent/US8273742B2/en active Active
- 2010-06-15 AU AU2010260244A patent/AU2010260244B2/en not_active Ceased
- 2010-06-15 MA MA34455A patent/MA33363B1/fr unknown
- 2010-06-15 WO PCT/US2010/038568 patent/WO2010147917A1/en not_active Ceased
- 2010-06-15 DK DK10726756.9T patent/DK2443104T3/da active
- 2010-06-15 UA UAA201114996A patent/UA106755C2/uk unknown
- 2010-06-15 JP JP2012516178A patent/JP5596139B2/ja active Active
- 2010-06-15 SI SI201030200T patent/SI2443104T1/sl unknown
- 2010-06-15 SG SG2011094190A patent/SG177289A1/en unknown
- 2010-06-15 KR KR1020117030157A patent/KR101389165B1/ko not_active Expired - Fee Related
- 2010-06-15 CN CN201080027189.3A patent/CN102459233B/zh active Active
- 2010-06-15 PE PE2011002119A patent/PE20121050A1/es active IP Right Grant
- 2010-06-15 PL PL10726756T patent/PL2443104T3/pl unknown
- 2010-06-15 NZ NZ596882A patent/NZ596882A/xx not_active IP Right Cessation
- 2010-06-15 BR BRPI1011601A patent/BRPI1011601A2/pt not_active Application Discontinuation
- 2010-06-15 ES ES10726756T patent/ES2409054T3/es active Active
- 2010-06-15 CA CA2764542A patent/CA2764542C/en not_active Expired - Fee Related
- 2010-06-15 EA EA201270049A patent/EA019059B1/ru not_active IP Right Cessation
-
2011
- 2011-11-22 ZA ZA2011/08587A patent/ZA201108587B/en unknown
- 2011-11-24 IL IL216599A patent/IL216599A/en not_active IP Right Cessation
- 2011-11-29 HN HN2011003139A patent/HN2011003139A/es unknown
- 2011-12-07 TN TNP2011000627A patent/TN2011000627A1/en unknown
- 2011-12-08 CR CR20110658A patent/CR20110658A/es unknown
- 2011-12-13 DO DO2011000386A patent/DOP2011000386A/es unknown
- 2011-12-14 CL CL2011003147A patent/CL2011003147A1/es unknown
- 2011-12-16 EC EC2011011541A patent/ECSP11011541A/es unknown
- 2011-12-22 CO CO11177210A patent/CO6480932A2/es not_active Application Discontinuation
-
2012
- 2012-08-21 US US13/590,481 patent/US9000023B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201108587B (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| IL208211A0 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| IL211841A0 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| ZA201400310B (en) | Solid dosage form | |
| GB0909680D0 (en) | Dosage form | |
| IL237392A0 (en) | Pharmaceutical combination | |
| IL220091A0 (en) | Pcsk9 antagonists | |
| GB2473319B (en) | Removable hydraulic-set packer | |
| AP3250A (en) | Tablets for combination therapy | |
| ZA201304617B (en) | Orally disintegrating tablet | |
| EP2389068A4 (en) | HEMGE OF THE HEDGEHOG SIGNAL PATH | |
| ZA201304366B (en) | Orally disintegrating tablet | |
| ZA201200761B (en) | Tablet | |
| AU330360S (en) | Tablet | |
| IL208953B (en) | Pharmaceutical combination | |
| GB0920041D0 (en) | Tablet | |
| HK1153467A (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| GB0900643D0 (en) | Dosage assembly | |
| AU330359S (en) | Tablet | |
| AU331949S (en) | Tablet | |
| GB0910772D0 (en) | Pharmaceutical | |
| GB0918829D0 (en) | Monitor |